Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.

Author: BauerA, ElsnerP, MahlerV, MolinS, NielsenT S S, WormM

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Topical delgocitinib ointment was effective and well tolerated in a randomized, double-blind, phase IIa study of 91 patients with chronic hand eczema. Treatment success was achieved in 46% of patients receiving delgocitinib versus 15% of patients receiving vehicle (odds ratio 4.89). Further clinical studies are warranted to confirm these findings.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Management of chronic hand eczema (CHE) remains a challenge; effective topical treatment is limited to corticosteroids. OBJECTIVES: To assess the efficacy and safety of a novel, pan-Janus kinase inhibitor (delgocitinib) in patients with CHE. METHODS: In this randomized, double-blind, p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bjd.18469

データ提供：米国国立医学図書館（NLM）

Topical Delgocitinib: A Promising Treatment for Chronic Hand Eczema

This phase IIa clinical trial evaluates the efficacy and safety of topical delgocitinib, a novel pan-Janus kinase inhibitor, in patients with chronic hand eczema (CHE). The researchers found that delgocitinib ointment was significantly more effective than vehicle in achieving treatment success, with a favorable safety profile. This study suggests that topical delgocitinib holds promise as a new treatment option for patients with CHE, offering a potential alternative to traditional corticosteroid therapies.

Delgocitinib: A New Hope for Chronic Hand Eczema

The findings of this study offer a glimmer of hope for patients suffering from CHE. Delgocitinib's efficacy and favorable safety profile suggest it could be a valuable new therapeutic option for this challenging condition. Further research is warranted to confirm these findings and explore the potential of delgocitinib in treating CHE.

Navigating the Treatment Landscape for Chronic Hand Eczema

This study underscores the need for innovative therapies to address the unmet needs of patients with CHE. The research highlights the potential of delgocitinib as a new therapeutic agent, expanding the options available to clinicians for managing this chronic and often debilitating condition.

Dr. Camel's Conclusion

This research offers a refreshing perspective on the treatment of CHE, providing a potential oasis of relief for patients struggling with this chronic condition. Delgocitinib's promising efficacy and safety profile suggest it could be a valuable addition to the therapeutic arsenal, offering hope for improved outcomes and enhanced quality of life for individuals affected by CHE.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2021-05-14
Further Info :

Pubmed ID

31466119

DOI: Digital Object Identifier

10.1111/bjd.18469

Related Literature

Article Analysis
・Effective treatment of eczema
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.